Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data

被引：0
|
作者：
Gomez-Puerta, Jose A. [1 ,2 ]
Duque Zapata, Natalia [1 ]
Alonso Gonzalez, Luis [1 ,2 ]
Ceron, Carmen [1 ]
Vasquez, Monica [1 ]
Felipe Diaz, Oscar Jair [1 ,3 ]
机构：
[1] Medicarte IPS, Medellin, Colombia
[2] Univ Antioquia, Grp Reumatol, Medellin, Colombia
[3] Clin Las Vegas, Medellin, Colombia
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
RHEUMATOID-ARTHRITIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2489
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The real world drug survival of biologic therapies in Australasian Psoriasis Registry patients
    Cumming, S.
    Foley, P.
    Baker, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 43 - 43
  • [2] Adherence to biologic DMARD therapies in rheumatoid arthritis
    Koncz, Tamas
    Pentek, Marta
    Brodszky, Valentin
    Ersek, Katalin
    Orlewska, Ewa
    Gulacsi, Laszlo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (09) : 1367 - 1378
  • [3] SYSTEMATIC REVIEW: COMPARATIVE EFFECTIVENESS OF BIOLOGIC DMARD THERAPIES VERSUS TRADITIONAL DMARD THERAPIES IN RA
    Campbell, Richard C.
    Kingsley, Gabrielle
    Scott, David
    [J]. RHEUMATOLOGY, 2009, 48 : I63 - I63
  • [4] LOW RATES OF RETENTION OF BIOLOGIC DMARD MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITISIN REAL LIFE SETTINGS
    Lazarini, A.
    Thomas, K.
    Kaltsonoudis, E.
    Drosos, A.
    Tsatsani, P.
    Gazi, S.
    Pantazi, L.
    Boki, K. A.
    Katsimbri, P.
    Boumpas, D.
    Fragkiadaki, K.
    Tektonidou, M.
    Sfikakis, P. P.
    Karagianni, K.
    Sakkas, L.
    Grika, E.
    Vlachoyiannopoulos, P.
    Evangelatos, G.
    Iliopoulos, A.
    Dimitroulas, T.
    Garyfallos, A.
    Melissaropoulos, K.
    Georgiou, P.
    Areti, M.
    Georganas, C.
    Vounotrypidis, P.
    Kitas, G.
    Vassilopoulos, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1374 - 1374
  • [5] Real-world comparison of monotherapy and concomitant medication use with biologic therapies for psoriasis: Ixekizumab versus guselkumab
    Blauvelt, Andrew
    Burge, Russel
    Charbonneau, Bridget
    Malatestinic, William
    Zhu, Baojin
    Wang, Fangyu
    Lockshin, Benjamin
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB23 - AB23
  • [6] Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
    Weaver, AL
    Lautzenheiser, RL
    Schiff, MH
    Gibofsky, A
    Perruquet, JL
    Luetkemeyer, J
    Paulus, HE
    Xia, HA
    Leff, JA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (01) : 185 - 198
  • [7] Assessment of predictors of response to DMARD therapies in RA: Real world experience in radius
    Harrison, MJ
    Paulus, HE
    Mena, HR
    Lipstate, JM
    Xia, HA
    White, B
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 189 - 189
  • [8] PATTERNS OF BIOLOGIC DMARD MONOTHERAPY IN A LARGE NATIONWIDE RHEUMATOID ARTHRITIS COHORT: DATA FROM 1036 PATIENTS
    Thomas, K.
    Kaltsonoudis, E.
    Drosos, A.
    Papalopoulos, I.
    Sidiropoulos, P.
    Katsimbri, P.
    Boumpas, D.
    Tsatsani, P.
    Gazi, S.
    Grika, E. P.
    Vlachoyiannopoulos, P. G.
    Fragiadaki, K.
    Tektonidou, M.
    Sfikakis, P. P.
    Karagianni, K.
    Sakkas, L. I.
    Pantazi, L.
    Boki, K.
    Dimitroulas, T.
    Garyfallos, A.
    Kasimos, D.
    Evangelatos, G.
    Iliopoulos, A.
    Georganas, C.
    Vounotrypidis, P.
    Areti, M.
    Georgiou, P.
    Delis, K.
    Mavragani, K.
    Bournazos, I.
    Katsifis, G.
    Mavromatis, C.
    Kitas, G. D.
    Vassilopoulos, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 836 - 837
  • [9] Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
    Charles-Schoeman, C.
    Burmester, Gerd
    Nash, P.
    Zerbini, C. A. F.
    Anway, S.
    Kwok, K.
    Hendrikx, T.
    Bananis, E.
    Fleischmann, Roy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S212 - S213
  • [10] The ReAct trial:: Efficacy evaluation of adalimumab (Humira®) in patients switching from prior biologic DMARD therapies
    McKenna, F
    Bombardieri, S
    Tzioufas, AG
    Malaise, MG
    Webber, DG
    Kupper, H
    [J]. RHEUMATOLOGY, 2005, 44 : I2 - I3
12345